위더스제약
Financials
Valuation Metrics
위더스제약's Market Cap is ₩858B. At end of 2025 it was ₩1138B. Ranked #1322 of 2,410 in KR market (top 55%), #730 of 1,631 on KOSDAQ (top 45%), #147 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 64%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 85.80B KRW | KR#1,322/2,410 Sec#147/231 |
| Revenue | 111.72B KRW | KR#1,355/2,410 Sec#86/231 |
| Net Income | 7.96B KRW | KR#1,040/2,410 Sec#65/231 |
| Total Assets | 144.03B KRW | KR#1,537/2,410 Sec#115/231 |
| Net Assets | 103.94B KRW | KR#1,386/2,410 Sec#108/231 |
| Employees | 218 | KR#1,032/2,410 Sec#85/231 |
| Value | ||
| P/E | 10.77x | KR#917/2,410 Sec#46/231 |
| P/B | 0.83x | KR#1,358/2,410 Sec#82/231 |
| PEG | 0.32x | KR#654/2,410 Sec#39/231 |
| P/S | 0.77x | KR#1,271/2,410 Sec#67/231 |
| EV/EBITDA | 20.89x | KR#1,069/2,410 Sec#64/231 |
| FCF Yield | 6.39% | KR#806/2,410 Sec#39/231 |
| Profitability | ||
| ROE | 7.66% | KR#823/2,410 Sec#57/231 |
| ROA | 5.53% | KR#677/2,410 Sec#55/231 |
| Op. Margin | 3.65% | KR#1,143/2,410 Sec#83/231 |
| Revenue Growth | 9.00% | KR#951/2,410 Sec#93/231 |
| Earnings Growth | 33.19% | KR#631/2,410 Sec#42/231 |
| Financial Health | ||
| Debt Ratio | 38.58% | KR#756/2,410 Sec#90/231 |
| Total Debt | 18.17B KRW | KR#1,407/2,410 Sec#114/231 |
| FCF | 5.48B KRW | KR#878/2,410 Sec#59/231 |
| Cash | 18.87B KRW | KR#1,279/2,410 Sec#95/231 |
| Current Ratio | 2.04x | KR#846/2,410 Sec#96/231 |
| Net Debt/EBITDA | -0.17x | KR#573/2,410 Sec#33/231 |
| Dividend | ||
| Div. Growth | 108.40% | KR#110/2,410 Sec#3/231 |
| Performance | ||
| 1Y Return | -0.46% | KR#624/2,410 Sec#35/231 |
| 1M Return | -10.34% | KR#1,176/2,410 Sec#117/231 |
| From 52W High | -45.61% | KR#973/2,410 Sec#67/231 |
| 1Y MDD | -49.66% | KR#940/2,410 Sec#74/231 |
| Trading | ||
| Volume | 48,918 shares | KR#700/2,410 Sec#72/231 |
| Trading Value | 316.6M KRW | KR#747/2,410 Sec#81/231 |
| Foreign Own. | 1.33% | KR#1,891/2,410 Sec#186/231 |
| Per Share | ||
| EPS | 603 KRW | KR#923/2,410 Sec#63/231 |
| BPS | 7,874 KRW | KR#1,145/2,410 Sec#84/231 |
Company Info
Withus Pharmaceutical, headquartered in Seocho-gu, Seoul, was established in 2004 and listed on KOSDAQ in 2020, with its primary business being the production and sale of specialized medicines. The company demonstrates strengths in cardiovascular drugs, operates cephalosporin antibiotic production facilities, and engages in Contract Manufacturing Organization (CMO) services. To expand its market share in aging population and chronic disease markets, Withus Pharmaceutical is strengthening its product lineup and pharmaceutical pipeline. It is also enhancing capabilities by securing manufacturing technologies through strategic collaborations.